The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| DBVT | +332% | -1.18% | -0.24% | -95% |
| S&P | +14.5% | +93.32% | +14.09% | +243% |
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.
"The New England Journal of Medicine" reported phase 3 trial details regarding the company's peanut allergy treatment for toddlers.
The company can now move forward with a late-stage study of its lead pipeline candidate.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$4.62M | -11.2% |
| Market Cap | $250.47M | 225.1% |
| Market Cap / Employee | $2.30M | 0.0% |
| Employees | 109 | 4.8% |
| Net Income | -$42.40M | -28.0% |
| EBITDA | -$38.49M | -24.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $103.21M | 55.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $6.70M | -1.3% |
| Short Term Debt | $7.89M | 24.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -95.32% | -42.0% |
| Return On Invested Capital | -120.74% | -51.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$34.37M | 4.0% |
| Operating Free Cash Flow | -$34.33M | 2.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.25 | 1.10 | 2.43 | 65.44 | 9385.71% |
| Price to Tangible Book Value | 4.26 | 1.10 | 2.43 | 66.11 | 1815.47% |
| Enterprise Value to EBITDA | -1.02 | -1.80 | -5.63 | -3.15 | 417.34% |
| Return on Equity | -103.1% | -135.7% | -198.2% | -148.5% | 104.40% |
| Total Debt | $14.99M | $15.09M | $12.35M | $14.59M | 11.18% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
